Cargando…

Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT

Gallbladder cancer (GBC) is characterized by poor prognosis, early metastasis, and high recurrence rates, which seriously threaten human health. The effect of lenvatinib, a widely used drug in anti-hepatocellular carcinoma in China, on GBC progress, as well as its underlying molecular mechanism, rem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Jianwen, Qi, Lei, Liang, Jialu, Zong, Ke, Liu, Wentao, Li, Renfeng, Feng, Ruo, Zhai, Wenlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120192/ https://www.ncbi.nlm.nih.gov/pubmed/33995632 http://dx.doi.org/10.7150/jca.50292

Ejemplares similares

Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer
por: Ye, Jianwen, et al.
Publicado: (2021)

Metformin suppresses hypoxia-induced migration via the HIF-1α/VEGF pathway in gallbladder cancer in vitro and in vivo
por: Ye, Jianwen, et al.
Publicado: (2019)

Calreticulin down-regulation inhibits the cell growth, invasion and cell cycle progression of human hepatocellular carcinoma cells
por: Feng, Ruo, et al.
Publicado: (2015)

A comparative study of robotics and laparoscopic in minimally invasive pancreatoduodenectomy: A single-center experience
por: Zong, Ke, et al.
Publicado: (2022)

Single-cell transcriptomics analysis reveals intratumoral heterogeneity and identifies a gene signature associated with prognosis of hepatocellular carcinoma
por: Liang, Jialu, et al.
Publicado: (2022)

Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
por: Honda, Shuya, et al.
Publicado: (2019)

Interleukin 17A promotes gallbladder cancer invasiveness via ERK/NF-κB signal pathway mediated epithelial-to-mesenchymal transition
por: Chen, Kunlun, et al.
Publicado: (2020)

Lenvatinib resistance mechanism and potential ways to conquer
por: Bo, Wentao, et al.
Publicado: (2023)

TGF-β- and lipopolysaccharide-induced upregulation of circular RNA PWWP2A promotes hepatic fibrosis via sponging miR-203 and miR-223
por: Liu, Wentao, et al.
Publicado: (2019)

Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
por: Hao, Jianwen, et al.
Publicado: (2021)

Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells
por: Chen, Kunlun, et al.
Publicado: (2021)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Dioscin Induces Gallbladder Cancer Apoptosis by Inhibiting ROS-Mediated PI3K/AKT Signalling
por: Song, Xiaoling, et al.
Publicado: (2017)

Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition
por: ZHOU, CHUANG, et al.
Publicado: (2015)

Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2
por: Duan, Anqi, et al.
Publicado: (2022)

Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy
por: Dai, Mu-Gen, et al.
Publicado: (2023)

Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
por: Suyama, Koichi, et al.
Publicado: (2018)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

EnACP: An Ensemble Learning Model for Identification of Anticancer Peptides
por: Ge, Ruiquan, et al.
Publicado: (2020)

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2022)

Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma
por: Lu, Xu, et al.
Publicado: (2016)

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
por: Xiao, Yongqiang, et al.
Publicado: (2023)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
por: Sun, Qi, et al.
Publicado: (2022)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023)

Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells
por: Wen, Xianchun, et al.
Publicado: (2018)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

NEAT1–SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines
por: Tsuchiya, Hiroyuki, et al.
Publicado: (2023)

Clinical significance of sarcopenia in the treatment of patients with primary hepatic malignancies, a systematic review and meta-analysis
por: Zhang, Guoqing, et al.
Publicado: (2017)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
por: Trevisan, Matteo, et al.
Publicado: (2022)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
por: Zhou, Nan, et al.
Publicado: (2023)

Lenvatinib: T3 thyrotoxicosis: case report
Publicado: (2021)

Thrombotic microangiopathy associated with lenvatinib therapy
por: Contreras Angulo, Macarena, et al.
Publicado: (2023)

An Apoptotic Gene Signature for the Prognosis of Hepatocellular Carcinoma
por: Chen, Kunlun, et al.
Publicado: (2021)

Textbook outcome in gallbladder carcinoma after curative-intent resection: a 10-year retrospective single-center study
por: Li, Qi, et al.
Publicado: (2023)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_79qscrebi21h98mp1dlcv287vg